Heparin is a sulfur-containing polysaccharide that performs as an anticoagulant or a blood thinner. It impedes the development of blood clots inside blood vessels and is also used to treat heart conditions such as unstable angina. Heparin is also used during dialysis and blood transfusion, and post-surgeries. It is generally injected directly into the muscle or the veins to break down the clots and maintain the effortless fluidity of the blood. The growing old population is principally affected by venous thrombosis, which will boost heparin sales market growth. Venous thromboembolism (VTE) is highly frequent in the old population; although, it can occur at any age. The increasing occurrence of several diseases such as heart failure can result in thrombosis and is most likely to occur in old age than the young age population. However, the adverse effects, including high bleeding incurred with heparin, are the key impeding factors of the market. The Heparin Sales Market is expected to grow at the rate of 5.2% CAGR by 2026.

Research Methodology:

The Heparin Sales Market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Heparin Sales Market on the basis of Type

• Low Molecular Weight Heparin
• Ultra-low Molecular Weight Heparin
• Unfractionated Heparin

Heparin Sales Market on the basis of Application

• Venous Thromboembolism
• Atrial Fibrillation
• Renal Impairment
• Coronary Artery Disease
• Others

Heparin Sales Market on the basis of End-Use

• Outpatient
• Inpatient

Heparin Sales Market on the basis of Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

The low molecular weight heparin segment has the most significant share in the market. This is due to the high anticipated anticoagulant effect of the product. Moreover, the significant share is due to the high adoption of the low molecular weight heparin in the developed countries, the high pricing of these product offerings, and the more safety profiles of this type of product compared to other products.

Further, the venous thromboembolism segment is expected to register the highest growth rate over the forecasted years. The highest growth is attributed to the increasing awareness about thrombosis and the increasing cases of venous thromboembolism. The venous thromboembolism is further categorized into pulmonary embolism (PE) and deep vein thrombosis (DVT).

As per the end-user, the market is bifurcated into outpatient and inpatient. The outpatient segment is projected to have a substantial growth rate in the market. The preference for a subcutaneous route of administration among the patients is increasing, which is a key factor for the segment growth. Moreover, the cost of outpatient treatment is low when compared to inpatient hospital costs.

North America has held a maximum share in the heparin sales market compared to other regions. The maximum share is accredited to the growing injuries in sports and rising cardiovascular disorders. In addition, the huge healthcare expenditure levels, rising patient awareness, and experienced healthcare infrastructure in this region are the factors attributed to the region’s maximum share.

Few factors that are majorly accelerating the global heparin market growth are the rising number of accidents and medical surgeries globally, which is increasing demand for heparin. The growing disorders such as cardiovascular disorders will spur the demand for heparin. An increase in the investments to develop healthcare infrastructure and the increasing awareness among patients are also expected to boost the market demand.

The major market companies of the heparin sales market include Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Aspen Pharmacare Holdings Ltd., Baxter International Inc., Laboratorios Farmaceuticos Rovi SA, Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Mylan NV, Pfizer Inc., and Sanofi S.A.

Henceforth, the increasing prevalence of the diseases such as coronary heart disease and myocardial infections and the increasing number of accidents and injuries lead to blood clots during surgeries. Heparin is playing a prominent role in preventing blood clots from forming.

• This report of the heparin sales market consists of qualitative factors such as factors propelling and restraining and generating opportunities.
• This study depicts the competitive analysis of significant players in the heparin sales market and their strategic developments in the product.
• This research provides the analysis based on qualitative and quantitative of the market segmented.
• Additionally, this report consists of actual market shares and forecasts for all the segments which are mentioned in the report.

1. Executive Summary
2. Industry Outlook
   1. Industry Overview
   2. Industry Trends
3. Market Snapshot
   1. Market Definition
   2. Market Outlook
      1. Porter Five Forces
   3. Related Markets
4. Market characteristics
   1. Market Overview
   2. Market Segmentation
   3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
   4. DRO - Impact Analysis
5. Type: Market Size & Analysis
   1. Overview
   2. Low Molecular Weight Heparin
   3. Ultra-low Molecular Weight Heparin
   4. Unfractionated Heparin
6. Application: Market Size & Analysis
   1. Overview
   2. Venous Thromboembolism
   3. Atrial Fibrillation
   4. Renal Impairment
   5. Coronary Artery Disease
   6. Others
7. End-Use: Market Size & Analysis
   1. Overview
   2. Outpatient
   3. Inpatient
8. Geography: Market Size & Analysis
   1. Overview
   2. North America
   3. Europe
   4. Asia Pacific
   5. Rest of the World
9. Competitive Landscape
   1. Competitor Comparison Analysis
   2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
10. Vendor Profiles
    1. Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    2. Aspen Pharmacare Holdings Ltd.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    3. Baxter International Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    4. Laboratorios Farmaceuticos Rovi SA
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    5. Eisai Co. Ltd.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    6. Fresenius SE & Co. KGaA
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    7. Hikma Pharmaceuticals Plc
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    8. Mylan NV
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    9. Pfizer Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    10. Sanofi S.A.
        1. Overview
        2. Financial Overview
        3. Product Offerings
        4. Developments
        5. Business Strategy
11. Analyst Opinion
12. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
       1. Data Collation and In-house Estimation
       2. Market Triangulation
       3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations